Infliximab in ulcerative colitis
نویسندگان
چکیده
Infliximab, a monoclonal anti-TNF-alpha antibody, is commonly used for treatment of moderate to severe Crohn's disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-alpha in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the efficacy of infliximab in the treatment of moderate to severe UC.
منابع مشابه
Economic Evaluation of Infliximab for Treatment of Refractory Ulcerative Colitis in Iran: Cost-Effectiveness Analysis
The aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe Ulcerative Colitis (UC) in Iran. We developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. Hypothetical patients, were individuals with moderate to sev...
متن کاملPatient and health professionals’ perspectives on the use of ciclosporin and infliximab when treating acute severe ulcerative colitis: an added dimension to the construct trial
Aim The COmparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis Trial (CONSTRUCT) aimed to compare the clinical and cost effectiveness of infliximab and ciclosporin in the treatment of steroid resistant acute severe ulcerative colitis, using quantitative, qualitative, and health economic data. The qualitative element explored patients’ and health professionals’ views of...
متن کاملMeta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis.
BACKGROUND Infliximab was approved for use in ulcerative colitis in recent years. It has been debated if infliximab increases the risk of post-operative complications in patients with ulcerative colitis. AIM To perform a meta-analysis that examines the relationship between preoperative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. METH...
متن کاملTrough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.
BACKGROUND AND AIMS Antibodies to infliximab reduce serum infliximab with loss of clinical benefit, but undetectable trough serum concentrations of infliximab may occur without antibody formation. The relationship between trough serum infliximab and clinical outcomes was evaluated in acute ulcerative colitis. METHODS In a cohort of 115 patients with ulcerative colitis treated with three-dose ...
متن کاملCase of Pyoderma Gangrenosum Associated with Ulcerative Colitis Successfully Treated with Infliximab
Pyoderma gangrenosum (PG) is a rare, ulcerating inflammatory skin disease. PG is often associated with systemic diseases, including inflammatory bowel disease (IBD). Herein, we report a case of PG associated with ulcerative colitis successfully treated with infliximab. Our case report supports the efficacy of infliximab for refractory case of PG with IBD.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 2 شماره
صفحات -
تاریخ انتشار 2008